New CEO Accelerating Virttu's Oncolytic Virus Drug Seprehvir
By Nuala Moran
Wednesday, September 19, 2012
LONDON Virttu Biologics Ltd. hired biotech veteran Steven Powell as CEO, with a brief to reshape strategy and turbo-charge efforts to commercialize oncolytic virus Seprehvir, a broad-spectrum product that has yet to reach the advanced stages of clinical development despite having been tested in more than 75 patients, in a number of solid tumors.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.